Krebs Ebitda from 2010 to 2024

KREBSBIO   104.14  8.79  7.78%   
Krebs Biochemicals' EBITDA is decreasing with slightly volatile movements from year to year. EBITDA is predicted to flatten to about -86.9 M. For the period between 2010 and 2024, Krebs Biochemicals, EBITDA quarterly trend regression had mean deviation of  65,775,779 and range of 420.9 M. View All Fundamentals
 
EBITDA  
First Reported
2008-03-31
Previous Quarter
-21.6 M
Current Value
-26.2 M
Quarterly Volatility
46.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Krebs Biochemicals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krebs Biochemicals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.5 M, Interest Expense of 41.6 M or Selling General Administrative of 5.7 M, as well as many indicators such as . Krebs financial statements analysis is a perfect complement when working with Krebs Biochemicals Valuation or Volatility modules.
  
This module can also supplement various Krebs Biochemicals Technical models . Check out the analysis of Krebs Biochemicals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Krebs Stock

Krebs Biochemicals financial ratios help investors to determine whether Krebs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Krebs with respect to the benefits of owning Krebs Biochemicals security.